Short-Term Safety and Efficacy of Onasemnogene Abeparvovec in 10 Patients with Spinal Muscular Atrophy: Cohort Study
Background. The efficacy and safety of onasemnogene abeparvovec have been demonstrated in patients with spinal muscular atrophy (SMA) in several clinical and observational studies. Gene replacement therapy results in Russian patients with SMA is not investigated yet.Objective. The aim of the study i...
Saved in:
Main Authors: | Kristina S. Nevmerzhitskaya (Author), Elena Yu. Sapego (Author), Daria A. Morozova (Author) |
---|---|
Format: | Book |
Published: |
"Paediatrician" Publishers LLC,
2021-12-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Spinal muscular atrophy - onasemnogene abeparvovec and other therapeutic options
by: Aleksandra Alicja Majchrzak-Celińska, et al.
Published: (2020) -
Expanding the Availability of Onasemnogene Abeparvovec to Older Patients: The Evolving Treatment Landscape for Spinal Muscular Atrophy
by: Charlotte A. René, et al.
Published: (2023) -
Early Development of Spinal Deformities in Children Severely Affected with Spinal Muscular Atrophy after Gene Therapy with Onasemnogene Abeparvovec-Preliminary Results
by: Venla Soini, et al.
Published: (2023) -
Interim Analysis of Treatment Outcomes of Young Children with 5q Spinal Muscular Atrophy on Gene Replacement Therapy with Onasemnogene Abeparvovec. Clinical Observations
by: Anna A. Kokorina, et al.
Published: (2023) -
Efficacy and safety of gene therapy with onasemnogene abeparvovec in children with spinal muscular atrophy in the D-A-CH-region: a population-based observational studyResearch in context
by: Claudia Weiß, et al.
Published: (2024)